# A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

> **NCT06868628** · PHASE2 · RECRUITING · sponsor: **Tiziana Life Sciences LTD** · enrollment: 5 (estimated)

## Conditions studied

- Multiple System Atrophy

## Interventions

- **DRUG:** Foralumab Nasal

## Key facts

- **NCT ID:** NCT06868628
- **Lead sponsor:** Tiziana Life Sciences LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-19
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06868628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06868628, "A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06868628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*